A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment

CONCLUSIONS: The emergence of lenvatinib has encouraged physicians to start systemic chemotherapy earlier in intermediatestage HCC patients.PMID:33639695

Source: Acta Gastro-Enterologica Belgica - February 28, 2021 Category: Gastroenterology Authors: T Hatanaka S Kakizaki T Nagashima T Ueno M Namikawa H Tojima D Takizawa A Naganuma H Arai K Sato N Harimoto K Shirabe T Uraoka Source Type: research